Free Trial
NASDAQ:MAZE

Maze Therapeutics (MAZE) Stock Price, News & Analysis

Maze Therapeutics logo
$13.14 -0.18 (-1.35%)
As of 08/8/2025 04:00 PM Eastern

About Maze Therapeutics Stock (NASDAQ:MAZE)

Key Stats

Today's Range
$12.95
$13.86
50-Day Range
$10.33
$17.78
52-Week Range
$6.71
$19.19
Volume
72,288 shs
Average Volume
155,301 shs
Market Capitalization
$575.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.60
Consensus Rating
Buy

Company Overview

Receive MAZE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maze Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MAZE Stock News Headlines

Analysts Set Maze Therapeutics, Inc. (NASDAQ:MAZE) PT at $25.60
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
MAZE Stock Price Quote | Morningstar
See More Headlines

MAZE Stock Analysis - Frequently Asked Questions

Maze Therapeutics' stock was trading at $13.38 at the start of the year. Since then, MAZE shares have decreased by 1.8% and is now trading at $13.14.

Maze Therapeutics, Inc. (NASDAQ:MAZE) announced its earnings results on Wednesday, May, 14th. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by $0.39.

Maze Therapeutics (MAZE) raised $140 million in an initial public offering (IPO) on Friday, January 31st 2025. The company issued 8,750,000 shares at $16.00 per share.

Maze Therapeutics's lock-up period expired on Wednesday, July 30th. Maze Therapeutics had issued 8,750,000 shares in its initial public offering on January 31st. The total size of the offering was $140,000,000 based on an initial share price of $16.00. Since the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Maze Therapeutics' top institutional shareholders include Geode Capital Management LLC (0.53%) and CWM LLC (0.01%).

Shares of MAZE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/14/2025
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MAZE
Previous Symbol
NASDAQ:MAZE
CIK
1842295
Web
N/A
Fax
N/A
Employees
121
Year Founded
N/A

Price Target and Rating

High Price Target
$34.00
Low Price Target
$17.00
Potential Upside/Downside
+94.8%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.10
Quick Ratio
16.10

Sales & Book Value

Annual Sales
$167.50 million
Price / Sales
3.44
Cash Flow
$0.15 per share
Price / Cash Flow
87.00
Book Value
($7.11) per share
Price / Book
-1.85

Miscellaneous

Outstanding Shares
43,800,000
Free Float
N/A
Market Cap
$575.53 million
Optionable
N/A
Beta
N/A

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:MAZE) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners